Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 295

Sort by

Sort Order Select

Journal Articles

Safety, tolerability and efficacy of mesutoclax to treat patients with myeloid malignancies

Qian Jiang, Huafeng Wang, Xingli Zhao, Suning Chen, Shuo Ma, Di Zhu, Weige Wang, Renbin Zhao, Jie Jin

Blood (2025) 146 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2025-3417

Published: 2025

Journal Articles

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

Blood (2025) 146 (Supplement 1): 3391.

https://doi.org/10.1182/blood-2025-3391

Published: 2025

Journal Articles

BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study

Min Yang, Haitao Meng, Jie Jin

Blood (2025) 146 (Supplement 1): 7610.

https://doi.org/10.1182/blood-2025-7610

Published: 2025

Journal Articles

Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study

Yunfei Lv, Kuang Chen, Chunmei Yang, De Zhou, Juying Wei, Wanzhuo Xie, Gongqiang Wu, Jingcheng Zhang, Qin Pan, Jie Jin, Yanhong Tong, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 7253.

https://doi.org/10.1182/blood-2025-7253

Published: 2025

Journal Articles

Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial

Peipei Ye, Renzhi Pei, Lihong Shou, Jie Jin, Hongyan Tong, Huifang Jiang, Linlong Xu, Jian Shen, Sai Chen, Gongqiang Wu, Dong Chen, Shuangyue Li, Jingcheng Zhang, Huang Li, Fujiang Song, Weiying Feng, Chao Hu, Ying Lu

Blood (2025) 146 (Supplement 1): 5960.

https://doi.org/10.1182/blood-2025-5960

Published: 2025

Journal Articles

Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study

Xuewu Zhang, Yunfei Lv, Xiang Zhang, Xingnong Ye, Chunmei Yang, Juying Wei, De Zhou, Wanzhuo Xie, Haitao Meng, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 3596.

https://doi.org/10.1182/blood-2025-3596

Published: 2025

Journal Articles

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Blood (2025) 146 (Supplement 1): 887.

https://doi.org/10.1182/blood-2025-887

Published: 2025

Journal Articles

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Yi Zhang, Hu Zhou, Zhijian Xiao, Minghui Duan, Sujun Gao, Guangsheng He, Hongmei Jing, Junmin Li, Liangming Ma, Huanling Zhu, Chunkang Chang, Xin Du, Mei Hong, Xin Li, Qingchi Liu, Wei WANG, Na Xu, Haiping Yang, Jie Jin

Blood (2025) 146 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2025-2029

Published: 2025

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Blood (2025) 146 (Supplement 1): 2039.

https://doi.org/10.1182/blood-2025-2039

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma

Min Yang, Yang Liang, Guorong Wang, Baijun Fang, Luqun Wang, Songfu Jiang, Yafei Wang, Heng Mei, Wei Yang, Yanjuan He, Wei Wang, Haichao Zhang, Houguo Wang, Jie Jin, Wenming Chen

Blood (2025) 146 (Supplement 1): 5822.

https://doi.org/10.1182/blood-2025-5822

Published: 2025

Journal Articles

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Blood (2025) 146 (Supplement 1): 5819.

https://doi.org/10.1182/blood-2025-5819

Published: 2025

Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Blood (2025) 146 (Supplement 1): 88.

https://doi.org/10.1182/blood-2025-88

Published: 2025

Journal Articles

AP-3 targets the mrgbp/Tip60/MYC axis to exert potent anti T-ALL effects in a Notch1 independent manner

Fenglin Li, Haihui Zhuang, Jie Jin, Ying Lu

Blood (2025) 146 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2025-3364

Published: 2025

Journal Articles

Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia

Yile Zhou, Liu Ge, Liping Mao, Yinjun Lou, Hao Ai, Qian Wang, Hongyan Tong, Jie Jin, Qingsong Yin, Huafeng Wang

Blood (2025) 146 (Supplement 1): 3336.

https://doi.org/10.1182/blood-2025-3336

Published: 2025

Journal Articles

Evaluation of ims-IP assay for the detection and typing of monoclonal immunoglobulins by mass spectrometry.

Yu Chen, Min Yang, Jie Jin, Haitao Meng

Blood (2025) 146 (Supplement 1): 7869.

https://doi.org/10.1182/blood-2025-7869

Published: 2025

Journal Articles

Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma

Chunmei Yang, Juying Wei, Ying Lu, Liping Mao, Min Yang, Huafeng Wang, De Zhou, Hongyan Tong, Jie Jin, Linjie Li, Beili Hu, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2025-1911

Published: 2025

Journal Articles

Integrating clinical features, long-term Outcomes and NGS-based mutational analysis in AYA patients with essential Thrombocythemia and polycythemia vera: A Multicenter Retrosepective study

Xiaojing Bao, Tian Zeng, Zhikang Zheng, Bingbing Wen, Rumeng Li, Hongyan Tong, Jie Jin, Jian Huang

Blood (2025) 146 (Supplement 1): 7352.

https://doi.org/10.1182/blood-2025-7352

Published: 2025

Journal Articles

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Qingchi Liu, Lihong Shou, Feng Zhang, Cuicui Wu, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2025) 146 (Supplement 1): 7351.

https://doi.org/10.1182/blood-2025-7351

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety, tolerability and efficacy of mesutoclax to treat patients with myeloid malignancies

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study

Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study

Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial

Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma

Isatuximab (Isa) subcutaneous (SC) via an on-body injector (OBI) vs isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): East asia subgroup results from the randomized, non-inferiority, phase 3 iraklia study

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

AP-3 targets the mrgbp/Tip60/MYC axis to exert potent anti T-ALL effects in a Notch1 independent manner

Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia

Evaluation of ims-IP assay for the detection and typing of monoclonal immunoglobulins by mass spectrometry.

Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma

Integrating clinical features, long-term Outcomes and NGS-based mutational analysis in AYA patients with essential Thrombocythemia and polycythemia vera: A Multicenter Retrosepective study

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only